Failure Museum.Made with ❤️ by Aniruddh Jangid
Submit a case

EXHIBIT 065 · HEALTHCARE

DePuy ASR: implant performance after release

The ASR system was recalled following higher-than-expected revision rates.

OrganizationDePuy Orthopaedics
Period2010
LocationGlobal
StatusRecalled
ImpactCritical
EvidenceRegulatory documentation
Compare

Illustrative draft · Source-backed synopsis · Museum analysis marked separately · Updated 5 October 2026

DePuy ASR XL hip replacement components shown in Figure 2 of Wienroth, McCormack and Joyce’s 2014 study: femoral head, acetabular cup, and femoral stem.
DePuy ASR XL hip replacement components shown in Figure 2 of Wienroth, McCormack and Joyce’s 2014 study: femoral head, acetabular cup, and femoral stem.Matthias Wienroth, Pauline McCormack and Thomas J. Joyce / Life Sciences, Society and Policy (2014), Figure 2. Extracted and resized. Photograph · CC BY 4.0 · Resized for display.
01 / EXECUTIVE SUMMARY

The outcome is only the beginning.

The ASR system was recalled following higher-than-expected revision rates. [1]

THE PRINCIPLE TO CARRY FORWARD

Design surveillance around patient outcomes and revision signals, with clear thresholds for independent review.

02 / THE PROMISE

What the system was trying to do.

Restore mobility through a hip implant.

Museum interpretation

The assumption beneath the promise

Museum hypothesis to examine: Approval and early performance predict long-term outcomes without continuing independent surveillance. This is an analytical proposition to test against the record, not an attributed statement by the organization.

Success should be assessed against the intended service and its safety, reliability, or integrity constraints. A headline outcome cannot tell us whether those constraints were visible, tested, or owned before the event.

03 / WHAT HAPPENED

A sequence, not a single moment.

The intended system

Restore mobility through a hip implant.

Source-backed synopsis

The event or review

The ASR system was recalled following higher-than-expected revision rates. [1]

Source-backed synopsis

The documented aftermath

The manufacturer issued a recall and clinical follow-up guidance. [1]

Source-backed synopsis
Timeline of documented milestones. Gaps are not evidence that nothing happened. Sources: [1]
04 / WARNING SIGNS

What could be seen at the time?

Documented in cited record

Post-market evidence challenged expectations about device performance. [1]

Who could see it?

See the cited investigation for named teams and the information they held. The synopsis does not infer awareness by every stakeholder.

Why was it not enough?

Signals need interpretation, authority, and a route to action. This is an analytical question, not proof that a warning was deliberately ignored.

05 / KEY DECISIONS

Choices made within constraints.

Museum analysis: A permanent implant required ongoing outcome monitoring after approval and sale.

Available alternatives

Pause, test, narrow the operating envelope, seek independent review, or build a recovery option. These are proposed analytical alternatives; feasibility at the time is not established.

Information available

Post-market evidence challenged expectations about device performance. [1]

Incentives & constraints

Delivery pressure, cost, authority, and incomplete knowledge may shape a decision. Their specific weight is not established by this synopsis.

Risk accepted

Ask whether the relevant risk was recognized, who had authority to accept it, and whether affected people understood its implications.

06 / SYSTEM MAP

How conditions connected.

Select a node to inspect its evidence. Links show a proposed analytical relationship, not a measured causal effect.

05 / External context04 / Warning signal03 / Decisions02 / Technical conditions01 / Trigger06 / Consequences
Triggering event

The ASR system was recalled following higher-than-expected revision rates. [1]

Legend: numbered nodes = analytical categories; dashed arrows = proposed influence or propagation. Museum interpretation informed by the sources below. Feedback and omitted influences require further investigation.
07 / CONSEQUENCES

Beyond the immediate event.

Patients faced the possibility of further surgery and follow-up assessment. [1]

Human impactOperational impactRegulatory impact

Categories identify documented or relevant consequences. Financial, human, and environmental totals are not estimated here when the source base does not support them.

08 / WHAT THE MODELS EXPLAIN

More than one lens.

Analytical lens

Swiss Cheese Model

Harm can pass through gaps in multiple defenses: organizational influences, supervision, preconditions, and active failures.

In this case, use the lens to examine post-market surveillance. This application is museum interpretation, not a finding of the original investigation.

Limit: A useful lens, not proof of a universal linear cause. Barriers interact and change over time.

Analytical lens

High Reliability Organizations

Study practices that support attentive, resilient operation in hazardous settings.

In this case, use the lens to examine post-market surveillance. This application is museum interpretation, not a finding of the original investigation.

Limit: Introductory guide. This lens generates questions; it does not establish causation or replace case-specific evidence.

Analytical lens

Systems thinking

Examine relationships, boundaries, feedback, and incentives across a whole system.

In this case, use the lens to examine post-market surveillance. This application is museum interpretation, not a finding of the original investigation.

Limit: A broad lens needs explicit boundaries and evidence to avoid explaining everything after the fact.

09 / COUNTERFACTUALS

What could have changed the outcome?

Counterfactuals are hypotheses. They identify possible intervention points without claiming that a different choice would certainly have prevented the event.

INTERVENTION 2 / During early testing

Test the operating envelope

Exercise realistic boundary conditions and shared dependencies rather than validating components only in isolation.

Cost & feasibility

Requires time and independent review before commitment.

Likely effectiveness

May reduce exposure or consequences. Not quantified; feasibility and effect must be assessed against evidence available at the time.

10 / LESSONS

From hindsight to a usable practice.

FOR FOUNDERS

Design surveillance around patient outcomes and revision signals, with clear thresholds for independent review.

Before accelerating hiring or spending, name the assumptions that remain untested and set evidence thresholds for the next commitment.

11 / AFTERWARD

Recovery is another investigation.

The manufacturer issued a recall and clinical follow-up guidance. [1]

A corrective action is evidence of a response; it is not, by itself, evidence that the wider pattern has disappeared.

12 / SOURCES & EVIDENCE

Follow the record.

Documented claims are linked to sources. Analytical applications, lessons, and intervention proposals are museum interpretation. This draft does not establish motives or a single complete causal explanation.

  1. 1
    accessdata.fda.gov — DePuy Orthopaedics case record

    Regulatory documentation · Accessed 4 October 2026

Editorial history & limits

Version 1 · 4 October 2026 — source-backed illustrative synopsis created. Independent editorial review is pending. No claim of exhaustive investigation. New sources may alter the analysis.